TileDB Recognized in Two Gartner® Hype Cycle™ Reports for Healthcare and Life Sciences 2025

We're pleased to announce that TileDB has been recognized as a Sample Vendor in two Gartner Hype Cycle reports: Hype Cycle for Life Science R&D, 2025 and Hype Cycle for Healthcare and Life Science Data, Analytics and AI, 2025 for the categories of Trusted Research Environments and Single-cell Multiomics Systems. Gartner positions both categories in the "emerging" maturity phase, indicating an inflection point in the Hype Cycle where early adopters can gain significant competitive advantages.

This recognition underscores TileDB's growing impact, pioneering the application of multimodal data to power the next generation of AI-driven drug discovery and precision medicine. 

Double Recognition: A Testament to TileDB's Versatility

TileDB appears in two critical innovation areas that are reshaping how life science organizations approach data management and analysis:

1. Trusted Research Environments

Market adoption: Adopted by 5-20% of the target market, indicating growing but still selective implementation across healthcare research institutions.

Maturity: This is an emerging technology category that's gaining momentum as organizations recognize the need for secure, collaborative research platforms.

Gartner defines trusted research environments as "scalable and secure healthcare research platforms that provide a collection of capabilities for the evolving needs of research institutions." The platforms in this category enable:

• Multimodal data management and sharing

• Differential user access controls

• Data and algorithmic marketplaces

• Standards-based ontologies and data enrichment

• Hybrid cloud capabilities and MLOps

• Advanced collaboration tools

2. Single-Cell Multiomics Systems

Market adoption: Still in early adoption phases with only 1-5% of the target audience currently implementing these solutions, reflecting the specialized and cutting-edge nature of this technology.

Maturity: This represents an emerging field that's rapidly evolving as the technology matures and becomes more accessible to research organizations

This category represents the cutting edge of precision medicine, where researchers can analyze multiple "omics" datasets (genomics, transcriptomics, proteomics, metabolomics) at the single-cell level. The solutions included in this category provide unprecedented insights into cellular heterogeneity and disease mechanisms.

TileDB is a Vendor of Choice

TileDB’s inclusion in Gartner's Hype Cycles alongside industry leaders showcases TileDB's position as a Sample Vendor. In the reports, both categories carry “high” Benefit Ratings, indicating that organizations implementing TileDB and other technologies in these categories can expect significant value realization.

The Growing Need for Multimodal Data Infrastructure

According to the Gartner reports, healthcare and life sciences organizations are experiencing several key trends that make TileDB's capabilities increasingly vital:

• Data-intensive discovery: Single-cell and spatial omics, coupled with massive imaging datasets, require scalable analytics platforms

• Cost and time pressures: Organizations need cloud-native platforms that can accelerate research while reducing infrastructure costs

• Regulatory compliance: Secure, compliant data management is essential for regulated research environments

TileDB's Unique Value Proposition

Our inclusion in these categories reflects the TileDB platform's ability to address the complex, multimodal data challenges facing modern healthcare and life sciences organizations.

• For Trusted Research Environments: TileDB provides secure, scalable data management specifically designed for sensitive research data. The platform supports complex, multimodal datasets while maintaining fine-grained access controls and comprehensive governance frameworks. Our cloud-native architecture offers flexible hybrid deployment options to meet diverse institutional requirements.

• For Single-Cell Multiomics Systems: TileDB delivers high-performance storage and analysis capabilities for massive, sparse datasets that are characteristic of single-cell research. The platform supports time-series and multi-dimensional genomics data, efficiently handling the complex data structures generated by advanced single-cell technologies. TileDB seamlessly integrates with leading bioinformatics workflows and tools, enabling researchers to leverage existing pipelines and methodologies.

TileDB: The Foundation for Innovation

As both categories are positioned in the "emerging" maturity phase, they indicate we're at an inflection point in the Hype Cycle where early adopters can gain significant competitive advantages. Gartner projects that these technologies will reach mainstream adoption within the next 5-10 years, making now the ideal time for organizations to evaluate and implement these capabilities.

This recognition validates what our users already know: TileDB is at the forefront of enabling breakthrough research through multimodal data infrastructure. Whether you're managing large-scale genomics datasets, building collaborative research platforms, or pushing the boundaries of single-cell analysis, TileDB provides the foundation for innovation.

We're excited to be recognized alongside the industry's leading innovators and remain committed to empowering researchers with the tools they need to accelerate scientific discovery and improve human health.

Ready to accelerate your life sciences research? Contact our team to learn more about our solutions for trusted research environments and multiomics data management. Register for early access to the next generation of the TileDB platform, TileDB Carrara.

Gartner, Hype Cycle for Healthcare and Life Science Data, Analytics and AI, 2025, 7 July 2025

Gartner, Hype Cycle for Life Science R&D, 2025, 7 July 2025

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

GARTNER and HYPE CYCLE are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.